Spanish pharmaceutical company

PharmaMar is a pharmaceutical company based in Madrid, Spain. It uses marine resources to develop drugs for cancer and Alzheimer's treatments. It is also involved in molecular testing, including COVID-19 testing, and genetic analysis. Its subsidiary, Sylentis, develops therapies that use RNA interference.[1] The company is listed on the Madrid Stock Exchange and is part of the IBEX 35.[2]


  1. "BRIEF-Zeltia to propose reverse merger with PharmaMar". Reuters. 2015-02-26. Retrieved 2023-03-14.
  2. "I.G.B.M | Precios sesión Bolsa de Madrid". BME Exchange (in Spanish). Retrieved 2023-03-14.